The Horizon Pharma plc team is comprised of proven senior executives with extensive commercial, development and transaction experience in the biopharmaceutical industry.
Chairman, President and Chief Executive Officer
Mr. Walbert joined Horizon Pharma in June 2008 as our president and chief executive officer and has served as chairman of our board of directors since 2010. Prior to joining Horizon Pharma plc, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Mr. Walbert served as executive vice president, commercial operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Mr. Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth.
Mr. Walbert received his B.A. in business from Muhlenberg College, in Allentown, Pennsylvania. Mr. Walbert serves as chairman of the board of Egalet Corporation (NASDAQ: EGLT) and the Illinois Biotechnology Industry Organization (iBIO) and sits on the board of directors of XOMA Corporation (NASDAQ: XOMA), Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC) and the Greater Chicago Arthritis Foundation. Mr. Walbert is also a member of the Illinois Innovation Council.
Executive Vice President, Chief Business Officer
Mr. Carey joined Horizon Pharma in March 2014 as our chief business officer. Prior to joining Horizon Pharma, Mr. Carey spent more than 11 years as managing director and head of the life sciences investment banking group at JMP Securities LLC, a full-service investment bank. Prior to JMP, Mr. Carey was a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. Mr. Carey also has held roles at Red Hen Bread, InStadium, Shearson Lehman Hutton and Ernst & Whinney. Mr. Carey has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings and private placements. He has also served as a financial advisor on mergers, acquisitions and strategic alliance transactions with a total deal value of more than $3 billion.
Mr. Carey holds a bachelor's degree from the University of Notre Dame.
Executive Vice President, Chief Financial Officer
Mr. Hoelscher joined Horizon Pharma in June 2014 as executive vice president, finance and became executive vice president, chief financial officer on October 1, 2014. Prior to joining Horizon Pharma, Mr. Hoelscher, served as senior vice president, finance–treasury and corporate development of OfficeMax, Inc., an office supply company, from August 2013 to June 2014, and as vice president, finance–treasury and corporate development from August 2012 to July 2013.
Mr. Hoelscher held various financial leadership roles over a 19 year career at Alberto Culver Company, a hair and skin beauty care company, including serving as vice president, finance integration from May 2011 to May 2012 following Unilever’s acquisition of Alberto Culver. Previously, Mr. Hoelscher was vice president, international finance and treasurer from 2010 to 2011 and vice president, corporate controller from 2004 to 2010. From 1993 to 2004, Mr. Hoelscher served in other positions of increasing responsibility at Alberto Culver, including manager, corporate accounting; director, corporate finance; senior director, corporate finance; and corporate controller. Mr. Hoelscher also served in various positions in the audit practice at KPMG LLP from 1986 to 1993.
Mr. Hoelscher received his B.S. in accountancy from the University of Illinois at Urbana-Champaign and is a certified public accountant.
Executive Vice President, Chief Operating Officer
Mr. Moze joined Horizon Pharma in June 2014 and in his current role is responsible for all business operations and project management including research and development, manufacturing, human resources and information technology. Prior to joining Horizon, Mr. Moze spent more than 26 years as Partner and Owner of Crystal Clear Communications, a consulting firm focused on working with Board of Directors, Chief Executive Officers and executive teams to develop and execute their corporate strategies. He focused his clients on clarity of their strategies as well as alignment of their structure and processes to maximize their value. In addition Mr. Moze would assist them to build the organizational behaviors and competencies that were needed to drive effective organizations. Mr. Moze has worked with Fortune 500 and 1,000 companies such as Abbott, Pepsi Bottling Group, W.W. Grainger, Genentech, Rockwell Automation and Manpower among others.
Prior to Crystal Clear, Mr. Moze was a founder and President of Review Services and Asset Management Group a Licensed Investment Advisory firm. Mr. Moze serves on the Board of Palermo Villa, a private company.
Mr. Moze is uniquely qualified to help develop our organizational capabilities to ensure our operational success.
Executive Vice President, General Counsel
Mr. Beeler joined Horizon Pharma in January 2013 and has more than 15 years of experience providing legal and business advice and counsel to businesses in the healthcare and life sciences industries. Prior to joining Horizon Pharma, Mr. Beeler served as associate general counsel for Fenwal, Inc., a global life sciences manufacturer of products for transfusion medicine. Prior to Fenwal, he was senior counsel, Business Development, Commercial, and Research and Development, at TAP Pharmaceutical Products and Takeda Pharmaceuticals North America and also previously served as chief compliance officer at Schwarz Pharma.
Mr. Beeler is licensed to practice law in the states of Illinois and Indiana. He received his JD from Indiana University School of Law, his MBA from Kellogg School of Management at Northwestern University and his BA from Purdue University.
Executive Vice President, Research and Development and Chief Medical Officer
Dr. Sherman joined Horizon Pharma in June 2009 as our executive vice president, development and regulatory affairs and chief medical officer. From June 2011 to September 2014, Dr. Sherman served as our executive vice president, development, manufacturing, and regulatory affairs, and chief medical officer. Since September 2014, Dr. Sherman has served as our executive vice president, research and development and chief medical officer.
From June 2009 through June 2010, Dr. Sherman served as president and board member of the Drug Information Association (DIA), a nonprofit professional association of members who work in government regulatory, academia, patient advocacy and the pharmaceutical and medical device industry. Dr. Sherman is a former president of DIA and serves as DIA liaison to the Clinical Trial Transformation Initiative (CTTI) a public-private partnership founded by the US Food and Drug Administration and Duke University to improve the quality and efficiency of clinical trials. He also serves on the Board of Advisors of the Center for Information and Study on Clinical Research Participation (CISCRP) a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media and policy makers about clinical research and the role each party plays in the process. He is an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and is a member of a number of professional societies, as well as a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine.
From August 2007 through June 2009, Dr. Sherman served as senior vice president of research and development and chief medical officer at IDM Pharma, which was acquired by Takeda in 2009. From June 2007 through August 2007, he served as vice president of clinical science at Takeda Global Research and Development. From September 2000 through June 2007, Dr. Sherman served as chief medical officer and executive vice president at NeoPharm, Inc., a biopharmaceutical company.
From October 1992 through August 2000, Dr. Sherman served as director, senior director and executive director of clinical research, and was head of oncology global medical operations at Searle/Pharmacia, or Searle, a pharmaceutical company. Prior to joining Searle, Dr. Sherman worked in clinical pharmacology and clinical research at Bristol-Myers Squibb Company, a biopharmaceutical company. Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed an internal medicine internship, residency and chief medical residency at Northwestern University, as well as fellowship training at the University of California, San Francisco (UCSF). Dr. Sherman was also a research associate at the Howard Hughes Medical Institute at UCSF.
Executive Vice President, Company Secretary and Managing Director, Ireland
Mr. Kelly joined Horizon Pharma in September 2014 as executive vice president, managing director, Ireland and was appointed company secretary in November 2014. Prior to joining Horizon Pharma, Mr. Kelly served as chief financial officer for Vidara Therapeutics, and was previously chief financial officer of AGI Therapeutics. He also served as senior vice president of Warner Chilcott (formerly Galen), a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company’s successful IPO on NASDAQ. In addition, Mr. Kelly also held roles in Elan Corporation and KPMG.
Mr. Kelly holds a bachelor’s degree in economics from Trinity College, Dublin and is also a member of the Institute of Chartered Accountants in Ireland (ACA).
Executive Vice President, Global Orphan Business Unit
Mr. Happel joined Horizon Pharma in October 2016 as part of the Raptor Pharmaceutical Corp. acquisition. He brings 30 years of experience in the healthcare industry into the role with the last 15 years dedicated to developing and commercializing treatments for rare diseases. Prior to joining Horizon, Mr. Happel was chief commercial officer at Raptor where he led the global commercialization of PROCYSBI® and QUINSAIR®. Prior to Raptor, he held chief commercial and corporate development roles at Allergen Research Corporation, a developer of treatments for food allergies, Dynavax Technologies, a drug development and vaccine company, and Aerovance, Inc., a biotechnology company. Mr. Happel also held senior-level leadership positions at Dr. Reddy's Laboratories, Inc., Chiron Corporation, InterMune, Inc. and Parke-Davis/Pfizer, where he led the development and commercialization of several market-leading products, including TOBI® for cystic fibrosis and ACTIMMUNE® for the treatment of multiple orphan diseases. Mr. Happel received a Bachelor of Arts in chemistry from Indiana University and an MBA in marketing from Indiana State University.
Executive Vice President, Rheumatology and Primary Care Business Units
Mr. Hampton joined Horizon Pharma in 2008 as a consultant and transitioned to a full-time employee in April 2015. He currently serves as executive vice president, primary care and rheumatology business units where he is tasked with leading the forward-looking strategy, as well as establishing operational goals for both business units. He has more than 20 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in rheumatology/autoimmune (HUMIRA), primary care (CELEBREX), orthopedic, diabetes (BYETTA), anti-infectives, and cardiovascular spaces. This includes 10 product launches in roles of increasing responsibility in sales, marketing and operations at G.D. Searle, Abbott Immunology (now AbbVie), and Amylin Pharmaceuticals. Most recently, George served as president and chief executive officer of a privately held technology company.